|
Hongene Biotech Corporation has announced its support of SiranBio’s SA1211 programme, a dual-target siRNA candidate for chronic hepatitis B, underscoring Hongene’s ability to deliver end-to-end development and manufacturing solutions for structurally complex oligonucleotide therapeutics.
Hongene Biotech Corporation supported the SA1211 programme with vertically integrated Contract Development and Manufacturing Organization services spanning raw materials production, process development, analytical development, current Good Manufacturing Practice drug substance and drug product manufacturing, and regulatory and CMC support.
The programme reflects the increasing complexity of next-generation siRNA therapeutics and highlights the importance of strong capabilities in synthesis, impurity control, scale-up, and clinical-stage manufacturing.
Biotech Corporation has demonstrated its advanced oligonucleotide contract development and manufacturing organization capabilities through its support of SiranBio’s SA1211 programme, a dual-target siRNA candidate for chronic hepatitis B, highlighting its ability to deliver end-to-end development and manufacturing for increasingly complex RNA therapeutics.
Through vertically integrated services spanning raw materials, process and analytical development, current Good Manufacturing Practice manufacturing, and CMC support, the program underscores the growing demands of next-generation siRNA and the importance of robust synthesis, scale-up, and impurity control.
“Programmes like SA1211 show where the field is heading,” said Dr. David Butler, chief technology officer at Hongene. “As siRNA designs become more complex, the bar for development and CMC execution rises with them. Our role is to give customers the technical depth and manufacturing flexibility to move these molecules forward with confidence.”
Dr. Butler added, “While SA1211 was manufactured using traditional solid-phase oligonucleotide synthesis, we are already applying our chemoenzymatic ligation platform to other complex dual-targeting siRNA programs in development. For next-generation constructs, we expect ligation to provide a highly attractive route to modular, high-purity, and scalable manufacturing.”
The SA1211 programme further reinforces Biotech Corporation’s position as a specialized contract development and manufacturing organization partner for innovative oligonucleotide therapeutics, particularly where molecular complexity and manufacturing execution are critical to program success.
Biotech Corporation is a global RNA technology provider and Contract Development and Manufacturing Organization, specializing in the design, synthesis, and large-scale manufacture of high-purity nucleic acid raw materials and therapeutics. Founded in 1998 and incorporated in Singapore, the company brings nearly 30 years of RNA-focused expertise to support biotech and pharmaceutical partners worldwide.
|